Trial intelligence / Profile preview

Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon20 Insertion Mutations

2022-502527-21-00Phase 2Authorised

Sponsor

Blueprint Medicines

Start

Oct 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

10